blog | Parabilis Medicines

Skip to content

Login

Login

Subscribe to our Newsletter

Go Back to Home

Go Back to Blog

IPOs, 2026, Parabilis Medicines

Parabilis Medicines Eyes $600 Million IPO as Lead Cancer Program Approaches Registrational Development

Eric Friedman

Jun 9, 2026 1:01:20 PM

Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering, ma...

Subscribe to our Newsletter

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025